Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
The Medicines Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s). The study will be a multicenter study in the United States.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- ORION-10
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1561
- sponsor
- The Medicines Company
- conditions
- ASCVD; Elevated Cholesterol
- interventions
- DRUG: Inclisiran Sodium; DRUG: Placebo
- start date
- 2017-12-21
- start date type
- ACTUAL
- primary completion date
- 2019-09-10
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT03399370
- Published
- Jan 16, 2018
- Updated
- Oct 5, 2020
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT03399370
- Categories
- ASCVD, Elevated Cholesterol
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials